The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: A meta-analysis

Taro Kishi, Shinji Matsunaga, Nakao Iwata

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Memantine is effective in the treatment of behavioral disturbances in patients with Alzheimer’s disease. It has not yet been fully determined which behavioral disturbances respond best to memantine. Methods: We conducted a meta-analysis of memantine vs control (placebo or usual care) for the treatment of individual behavioral disturbances (delusion, hallucination, agitation/aggression, dysphoria, anxiety/phobia, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity/activity disturbances, nighttime disturbance/diurnal rhythm disturbances, and eating disturbances). Randomized controlled studies of memantine in patients with Alzheimer’s disease were included in this study. To evaluate these outcomes, standardized mean difference (SMD), with 95% confidence intervals (95% CIs), based upon a random-effects model was evaluated in the meta-analysis. Results: A total of 11 studies (n=4,261; memantine vs placebo: N=4, n=1,500; memantine + cholinesterase inhibitors [M + ChEIs] vs ChEIs: N=7, n=2,761) were included in the meta-analysis. Compared to control, memantine showed significant improvement in agitation/aggression (SMD =-0.11; 95% CIs =-0.20, -0.03; P=0.01; I2=47%), delusion (SMD =-0.12; 95% CIs =-0.18, -0.06; P=0.0002; I2=0%), disinhibition (SMD =-0.08; 95% CIs =-0.15, -0.00; P=0.04; I2=0%), and nighttime disturbance/diurnal rhythm disturbances (SMD =-0.10; 95% CIs =-0.18, -0.02; P=0.02; I2=36%). Memantine was also marginally superior to control in hallucination (SMD =-0.06; 95% CIs =-0.12, 0.01; P=0.07; I2=0%) and irritability/lability (SMD =-0.09; 95% CIs =-0.19, 0.01; P=0.07; I2=42%). Memantine is similar to control in dysphoria, anxiety/ phobia, euphoria, apathy, and eating disturbance. Conclusion: The meta-analysis suggest that memantine has benefits for the treatment of most of the behavioral disturbances in patients with Alzheimer’s disease. Memantine does not deteriorate negative symptoms as behavioral disturbances in patients with Alzheimer’s disease.

Original languageEnglish
Pages (from-to)1909-1928
Number of pages20
JournalNeuropsychiatric Disease and Treatment
Volume13
DOIs
Publication statusPublished - 20-07-2017

Fingerprint

Memantine
Meta-Analysis
Alzheimer Disease
Confidence Intervals
Apathy
Delusions
Phobic Disorders
Hallucinations
Circadian Rhythm
Aggression
Anxiety
Eating
Placebos
Behavioral Symptoms
Cholinesterase Inhibitors
Motor Activity
Therapeutics

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{ea4a430152184edda0b6bb545a328349,
title = "The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: A meta-analysis",
abstract = "Background: Memantine is effective in the treatment of behavioral disturbances in patients with Alzheimer’s disease. It has not yet been fully determined which behavioral disturbances respond best to memantine. Methods: We conducted a meta-analysis of memantine vs control (placebo or usual care) for the treatment of individual behavioral disturbances (delusion, hallucination, agitation/aggression, dysphoria, anxiety/phobia, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity/activity disturbances, nighttime disturbance/diurnal rhythm disturbances, and eating disturbances). Randomized controlled studies of memantine in patients with Alzheimer’s disease were included in this study. To evaluate these outcomes, standardized mean difference (SMD), with 95{\%} confidence intervals (95{\%} CIs), based upon a random-effects model was evaluated in the meta-analysis. Results: A total of 11 studies (n=4,261; memantine vs placebo: N=4, n=1,500; memantine + cholinesterase inhibitors [M + ChEIs] vs ChEIs: N=7, n=2,761) were included in the meta-analysis. Compared to control, memantine showed significant improvement in agitation/aggression (SMD =-0.11; 95{\%} CIs =-0.20, -0.03; P=0.01; I2=47{\%}), delusion (SMD =-0.12; 95{\%} CIs =-0.18, -0.06; P=0.0002; I2=0{\%}), disinhibition (SMD =-0.08; 95{\%} CIs =-0.15, -0.00; P=0.04; I2=0{\%}), and nighttime disturbance/diurnal rhythm disturbances (SMD =-0.10; 95{\%} CIs =-0.18, -0.02; P=0.02; I2=36{\%}). Memantine was also marginally superior to control in hallucination (SMD =-0.06; 95{\%} CIs =-0.12, 0.01; P=0.07; I2=0{\%}) and irritability/lability (SMD =-0.09; 95{\%} CIs =-0.19, 0.01; P=0.07; I2=42{\%}). Memantine is similar to control in dysphoria, anxiety/ phobia, euphoria, apathy, and eating disturbance. Conclusion: The meta-analysis suggest that memantine has benefits for the treatment of most of the behavioral disturbances in patients with Alzheimer’s disease. Memantine does not deteriorate negative symptoms as behavioral disturbances in patients with Alzheimer’s disease.",
author = "Taro Kishi and Shinji Matsunaga and Nakao Iwata",
year = "2017",
month = "7",
day = "20",
doi = "10.2147/NDT.S142839",
language = "English",
volume = "13",
pages = "1909--1928",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease : A meta-analysis. / Kishi, Taro; Matsunaga, Shinji; Iwata, Nakao.

In: Neuropsychiatric Disease and Treatment, Vol. 13, 20.07.2017, p. 1909-1928.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease

T2 - A meta-analysis

AU - Kishi, Taro

AU - Matsunaga, Shinji

AU - Iwata, Nakao

PY - 2017/7/20

Y1 - 2017/7/20

N2 - Background: Memantine is effective in the treatment of behavioral disturbances in patients with Alzheimer’s disease. It has not yet been fully determined which behavioral disturbances respond best to memantine. Methods: We conducted a meta-analysis of memantine vs control (placebo or usual care) for the treatment of individual behavioral disturbances (delusion, hallucination, agitation/aggression, dysphoria, anxiety/phobia, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity/activity disturbances, nighttime disturbance/diurnal rhythm disturbances, and eating disturbances). Randomized controlled studies of memantine in patients with Alzheimer’s disease were included in this study. To evaluate these outcomes, standardized mean difference (SMD), with 95% confidence intervals (95% CIs), based upon a random-effects model was evaluated in the meta-analysis. Results: A total of 11 studies (n=4,261; memantine vs placebo: N=4, n=1,500; memantine + cholinesterase inhibitors [M + ChEIs] vs ChEIs: N=7, n=2,761) were included in the meta-analysis. Compared to control, memantine showed significant improvement in agitation/aggression (SMD =-0.11; 95% CIs =-0.20, -0.03; P=0.01; I2=47%), delusion (SMD =-0.12; 95% CIs =-0.18, -0.06; P=0.0002; I2=0%), disinhibition (SMD =-0.08; 95% CIs =-0.15, -0.00; P=0.04; I2=0%), and nighttime disturbance/diurnal rhythm disturbances (SMD =-0.10; 95% CIs =-0.18, -0.02; P=0.02; I2=36%). Memantine was also marginally superior to control in hallucination (SMD =-0.06; 95% CIs =-0.12, 0.01; P=0.07; I2=0%) and irritability/lability (SMD =-0.09; 95% CIs =-0.19, 0.01; P=0.07; I2=42%). Memantine is similar to control in dysphoria, anxiety/ phobia, euphoria, apathy, and eating disturbance. Conclusion: The meta-analysis suggest that memantine has benefits for the treatment of most of the behavioral disturbances in patients with Alzheimer’s disease. Memantine does not deteriorate negative symptoms as behavioral disturbances in patients with Alzheimer’s disease.

AB - Background: Memantine is effective in the treatment of behavioral disturbances in patients with Alzheimer’s disease. It has not yet been fully determined which behavioral disturbances respond best to memantine. Methods: We conducted a meta-analysis of memantine vs control (placebo or usual care) for the treatment of individual behavioral disturbances (delusion, hallucination, agitation/aggression, dysphoria, anxiety/phobia, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity/activity disturbances, nighttime disturbance/diurnal rhythm disturbances, and eating disturbances). Randomized controlled studies of memantine in patients with Alzheimer’s disease were included in this study. To evaluate these outcomes, standardized mean difference (SMD), with 95% confidence intervals (95% CIs), based upon a random-effects model was evaluated in the meta-analysis. Results: A total of 11 studies (n=4,261; memantine vs placebo: N=4, n=1,500; memantine + cholinesterase inhibitors [M + ChEIs] vs ChEIs: N=7, n=2,761) were included in the meta-analysis. Compared to control, memantine showed significant improvement in agitation/aggression (SMD =-0.11; 95% CIs =-0.20, -0.03; P=0.01; I2=47%), delusion (SMD =-0.12; 95% CIs =-0.18, -0.06; P=0.0002; I2=0%), disinhibition (SMD =-0.08; 95% CIs =-0.15, -0.00; P=0.04; I2=0%), and nighttime disturbance/diurnal rhythm disturbances (SMD =-0.10; 95% CIs =-0.18, -0.02; P=0.02; I2=36%). Memantine was also marginally superior to control in hallucination (SMD =-0.06; 95% CIs =-0.12, 0.01; P=0.07; I2=0%) and irritability/lability (SMD =-0.09; 95% CIs =-0.19, 0.01; P=0.07; I2=42%). Memantine is similar to control in dysphoria, anxiety/ phobia, euphoria, apathy, and eating disturbance. Conclusion: The meta-analysis suggest that memantine has benefits for the treatment of most of the behavioral disturbances in patients with Alzheimer’s disease. Memantine does not deteriorate negative symptoms as behavioral disturbances in patients with Alzheimer’s disease.

UR - http://www.scopus.com/inward/record.url?scp=85026402558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026402558&partnerID=8YFLogxK

U2 - 10.2147/NDT.S142839

DO - 10.2147/NDT.S142839

M3 - Article

AN - SCOPUS:85026402558

VL - 13

SP - 1909

EP - 1928

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -